AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase II study titled ‘A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology.’ The study aims to assess the efficacy and safety of T-DXd in patients with specific HER2 mutations who have limited treatment options.
The intervention being tested is Trastuzumab Deruxtecan (T-DXd), a drug administered via intravenous infusion, designed to target and treat solid tumors with HER2 activating mutations.
This interventional study follows a single-group, open-label design with no masking, focusing on treatment as its primary purpose. Patients are allocated to receive T-DXd monotherapy.
The study began on December 30, 2020, with primary completion expected by January 22, 2024, and the estimated study completion date set for June 26, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting future treatment approvals and market strategies.
The update on this study could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence and market position, especially in the competitive oncology sector. Competitors in the industry are closely monitoring such advancements, which could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.